Affiliation:
1. shfield Healthcare Communications Ltd.
Abstract
Patient adherence is a major problem in the treatment of inflammatory bowel disease (IBD). Research has shown that improved patient adherence and outcomes can be achieved if physicians are able to dedicate more time and attention to analysing patients’ feedback on their healthcare. The US Food and Drug Administration (FDA) has defined patient-reported outcomes (PROs) as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else.” Such patient reports may include various symptoms that are not obvious or that occur in the absence of an observer; they may describe the frequency and severity of a symptom, and the impact that it has on day-to-day life. They can describe factors such as patient satisfaction, productivity, use of resources, and health-related quality of life (QoL).
Interestingly, PROs do not always correlate with the physician’s view. Evidence has shown that physicians often underestimate the severity of a patient’s illness, report fewer problems than patients, and overestimate the improvements of treatment. In order to improve the value of PROs, physicians must engage patients in their disease management, otherwise known as patient empowerment. Empowerment can improve treatment success.
As it is becoming clearer that empowered and informed patients who are able to have a role in the decision-making have better outcomes, PROs will not only have further impact on the management of patients with IBD but also on health technology assessments and healthcare payer decisions.
Subject
Organic Chemistry,Biochemistry
Reference23 articles.
1. Gomollón F et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2016. [Epub ahead of print].
2. European Medicines Agency. Reflection Paper on the use of patient reported outcome 5 (PRO) measures in oncology studies. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500168852.pdf. Last accessed: 17 November 2016.
3. FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Deveopment to Support Labeling Claims. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf. Last accessed: 15 November 2016.
4. Deshpande PR et al. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2(4):137-44.
5. Breitscheidel L et al. Using patient-reported outcome assessments in clinical practice and their importance in risk management. J Med Econ. 2009;12(3):180-1.